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Abstract  
 
Importance: Psychosis and mania share conceptual, genetic, and clinical features, which 
suggest the possibility that they have common antecedents. Participants identified to be at-
risk for psychosis might also be at-risk for mania.  
Objective: We aimed to identify the rate and predictors of transition to mania in a cohort of 
youth at clinical high-risk for psychosis.  
Design: Five to 13-year longitudinal follow-up study  
Setting: Tertiary mental health service for young people in Melbourne, Australia 
Participants: Among a cohort of 416 young people at clinical high-risk for psychosis defined 
using the Ultra-High-Risk (UHR) criteria, 74.7% were followed up between 5 and 13 years 
from their baseline assessment.  
Exposures: Clinical characteristics and risk factors at baseline included i) the presence of 
threshold or subthreshold manic and depressive symptoms ii) medications and substance use 
iii) the severity of depression, anxiety, overall symptomatology, and positive and negative 
psychotic symptoms, iv) psychosocial functioning and v) family history.   
Main outcomes and measures: Transition to mania, the outcome of interest, was determined 
using either a structured clinical interview, or diagnoses from a state-wide public mental 
health contact registry. The presence of subthreshold symptoms, syndromes and treatments 
were established using the Structured Clinical Interview for Diagnosis as well as clinical 
notes. Family history was established using the Family Interview for Genetic Studies. 
Severity of depression, anxiety and general psychopathology were determined using 
Hamilton Depression and Anxiety Rating scales as well as the Brief Psychiatric Rating Scale. 
Functioning was measured using the Global Assessment of Functioning scale. These 
measures were compared between those who transitioned to mania and a subgroup of 
comparison participants who were individually matched on age, gender and baseline study.  
Results: Eighteen participants developed mania (UHR-M, 4.3%). In comparison with 
participants matched on age, gender and baseline-study who developed neither mania nor 
psychosis, more UHR-M participants had more subthreshold manic symptoms, more 
antidepressant use, and had lower psychosocial functioning at baseline.  
Conclusions and Relevance: In addition to the UHR criteria, additional features such as 
subthreshold manic symptoms and antidepressant use may help identify broader at-risk 
groups that predict the onset of mania in addition to transition to psychosis.  
 
Keywords: mania, psychosis, at-risk, bipolar disorder, sub-threshold, antidepressants, 
functioning, ultra-high risk, depression. 
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Introduction  
 
Prediction of the onset of mania may assist in prevention efforts and help to decrease the 
disability associated with this disorder 
1
. Early or preventive interventions 
2
 may also help 
prevent the possible decline in neurocognition 
3
 or the risk of recurrence 
4
 associated with 
onset of one or more manic episodes. Hence, methods to define clinical at-risk stages for 
bipolar disorder (BD) before the onset of frank manic episodes are important. A number of 
findings point to a relationship between psychotic symptoms and risk of development of BD. 
First, there are indicators of a genetic overlap between schizophrenia and BD in genome-
wide association studies 
5
. Second, there are common therapeutic agents for treatment of 
mania and psychosis, such as atypical antipsychotics, suggesting that similar 
pathophysiological processes underlie the expression of these disorders. Lastly, these two 
groups overlap considerably regarding biomarkers, including structural and functional brain 
changes, cognition and peripheral markers 
6
. Psychosis-at-risk samples may, thus, represent 
one of the common at-risk stages for BD, or more specifically, mania.  
 
Previous studies in at-risk cohorts for psychosis 
7
 have been limited by the lack of 
information on characteristics such as sub-threshold mood symptoms, which may represent a 
useful risk identification approach prior to the onset of mania 
8
. Further characterisation of 
pre-manic states may help identify a sub-group of participants within psychosis-at-risk 
clinical services. Additionally, such characteristics may add to the understanding of clinical 
prodromal characteristics for manic episodes.  
 
Thus, the aims of this study were: (i) to determine the rate of transition to mania; and (ii) 
identify the clinical risk factors associated with the onset of mania, among help-seeking 
Comment [SJ2]: Really the rate, or 
just the numbers who convert? 
youth aged 15-30 years who were at ultra-high-risk (UHR) for psychosis. As the study was 
exploratory, no a-priori hypotheses were posited. 
 
Methods:  
We used a prospective case-control design nested within a larger cohort study of help-seeking 
young people at ultra-high risk (UHR) of developing psychosis 
9,10
. All participants were part 
of a cohort of 416 young people aged 15 to 30 years, who were help-seeking and met criteria 
for being at UHR for psychotic disorder. The participants were recruited from a specialist 
clinic – the Personal Assessment and Crisis Evaluation (PACE) clinic – in a publically 
funded youth mental health service in Melbourne, Australia. The referral characteristics of 
the PACE clinic 
11
, and the UHR features for psychosis 
9
, have been previously described. 
Briefly, all participants had one or more of the following criteria: (i) attenuated psychotic 
symptoms; (ii) brief limited intermittent psychotic symptoms; and/or (iii) trait vulnerability 
for psychotic illness (schizotypal personality disorder or history of psychosis in a first-degree 
relative) along with deterioration in functioning or chronic low functioning. The exclusion 
criteria for entry to PACE clinic included a previous psychotic episode, an organic cause for 
presentation, and past total antipsychotic exposure equivalent to a haloperidol dosage of more 
than 15 mg. A detailed description of the cohort has been previously published 
12,13
. In 
addition, participants with full threshold BD I or II at baseline were excluded from the 
examination of incident mania in this study. Participants included in this study were recruited 
from five baseline studies 
12
 including two intervention studies (involving lithium and 
risperidone). The lithium intervention was not aimed at (sub)threshold manic or affective 
symptoms, but was an open label intervention for attenuated psychotic symptoms related to 
UHR status. Assessments in these studies were conducted by trained research assistants. The Comment [SJ3]: Can you reference 
the trial here? 
studies associated with this project were approved by the Melbourne Health Human Research 
Ethics Committee, and all participants provided written informed consent.  
 
Baseline Measures and risk factors/variables: The baseline data on subthreshold symptoms, 
use of substances or antidepressants and family history were extracted by the first author 
(AR, a consultant psychiatrist) from a number of sources including: (i) the Structured Clinical 
Interview for DSM-IV Axis I Disorders SCID-I/P, 
14
, including additional notes made by 
baseline assessors; (ii) Family Interview for Genetic Studies FIGS, 
15
; and (iii) patients’ 
clinical files. In case of discrepancies across these sources, these were resolved using clinical 
judgment of the primary author (a psychiatrist). BD I or II at baseline were excluded as 
possible diagnoses for all participants in the current study using SCID-I/P.  
 
The clinical risk factors examined at baseline included: 
i. subthreshold mania (equivalent to Other Specified BD in Diagnostic and Statistical 
Manual of Mental Disorders – Fifth Edition  DSM-5, 16 and subthreshold manic 
symptoms, defined as two or more mania symptoms at threshold/sub-threshold 
severity (rated 2 or 3 on the SCID-I/P) coded within the Current or Past section of 
mania or hypomania in SCID-I/P;  
ii. depression documented in SCID-I/P as major depressive episodes or minor depressive 
episodes;   
iii. family history of bipolar disorder, schizophrenia and/or psychotic disorders, and 
depression noted on the FIGS or in clinical files;   
iv. substance use, primarily alcohol, cannabis and stimulants, as recorded in the 
Substance Use Questionnaire 
17
. This was supplemented by information from clinical 
Comment [SJ4]: Is this the same 
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records. Cannabis and alcohol use severity was measured as the frequency of use in 
the preceding month as well as lifetime use; 
v. symptom severity measured using the Brief Psychiatric Rating Scale - total score 
(BPRS, 
18
), Scale for Assessment of Negative Symptoms (SANS, 
19
), Hamilton 
Rating Scale for Depression (HRSD, 
20
) , and the Comprehensive Assessment of At-
Risk Mental States (CAARMS, 
21
). The different domains of the CAARMS included 
disorders of thought content, perceptual abnormalities, conceptual disorganization, 
motor disturbances, disorders of concentration/attention/memory, disorders of 
emotions and affect, subjectively impaired energy and impaired tolerance to normal 
stress; 
vi. functioning as measured by the Global Assessment of Functioning scale (GAF, 22) 
scale and Heinrich’s Quality of Life Scale (QLS, 23).  
 
 
Follow-up:  
Among the participants initially assessed between 1993 and 2006, 74.8% (311) were 
followed up between 5 and 13 years later. The participants included in the study were 
followed up in two waves; first from October 2007 till May 2009 and the second from 
August 2012 till December 2013. In each follow-up wave, we contacted the participants and 
reassessed them using the SCID-I/P via face-to-face or telephone interviews. If the 
participants were could not able to be contacted, the state-wide mental health registry was 
examined to determine if there had been contact with public mental health services and the 
diagnoses provided if such contact had occurred. Given the accessibility of public mental 
health services for significant episodes of mental illness in Victoria, requirements of the local 
mental health legislation, limits of private practice services in Australia, and the high 
reliability of clinical diagnoses of BD I disorder diagnoses in general 
24,25
, it was considered 
that recorded manic episodes in the state-wide mental health registry were likely to be 
accurate.  
 
Two subgroups were derived from the cohort of participants who were followed up.  The first 
subgroup were those who later developed a manic episode after the baseline assessment 
according to DSM IV 
26
 criteria or equivalent (termed UHR –Manic transition or UHR-M). 
The second subgroup comprised participants individually matched on age and gender but 
who did not develop mania or threshold psychosis over the follow-up period (UHR- Non 
transitioned or UHR-NT). Threshold psychosis was defined as a week or more of one or 
more positive psychotic symptom at full severity/intensity, as per previous research 
12
.   
 
Matching: For each included participant who developed mania, a control participant was 
chosen by serially selecting the next participant in the individual baseline study on the basis 
of their gender being the same and their baseline age being no more than 3 years apart. When 
participants were prescribed lithium or risperidone as part of the baseline study, the 
medication prescribed was also matched. Participants with baseline diagnosis of BD I or II 
were excluded. 
 
 
Analyses:  
Baseline information was described using basic descriptive and inferential statistics. The 
included participants were compared with those who were not included using Mann Whitney 
U tests and chi-square (χ2) tests. Due to the relatively small numbers of participants in 
individual groups, the parametric assumptions were not met. Within the included sample (n= 
Formatted: Font: Italic
36), we performed McNemar’s tests for categorical variables and Wilcoxon signed rank tests 
for continuous variables to compare the baseline differences between the group that 
developed mania and those who did not. Effect sizes were calculated as the r score for the 
Wilcoxon-test obtained by dividing the z score by the square root of the total number of 
observations 
27
 and when possible, the weighted-average Odds Ratios (OR) for categorical 
variables.  
 
 
Results:  
 
Eighteen participants developed mania over the follow up period (4.3%, UHR-M). The same 
number of individually matched participants was selected (UHR-NT). The sample that was 
included (n= 36) did not differ from those who were not included (n=380) based on their age 
(z= -1.5, p= 0.12), gender (χ2=0.88, df= 1, p=0.35) or baseline educational status (χ2=6.75, 
df= 5, p=0.24). The mean length of follow-up for the included participants was 9.6 years 
(SD=2.2) and did not differ significantly between UHR-M and UHR-NT (p=0.92) groups 
(Table 1). One participant developed BD I within 6 months from baseline assessment but 
completed suicide in the month after this follow-up assessment.  
 
--- Table 1 about here.  
 
No participant was recorded as having used prescribed psychostimulant medication. The 
prevalence of daily cannabis use in the previous month was not different between those who 
later developed mania (50%) and those who did not (42.86%). Relatively few participants 
(twelve) were reliably assessed as having minor depression in the absence of major 
Comment [SJ5]: Previous to 
baseline or follow-up? 
depression or prior to the onset of major depression from case records or from SCID notes. 
The different domains of CAARMS were not different across the two groups, including those 
of energy or the quality of emotions measured in terms of their frequency or intensity of 
symptoms.  
 
--- Table 2 about here--- 
 
ORs could not be computed for the significantly different variables between groups such as 
subthreshold manic symptoms and antidepressant use due to low cell numbers (zero pairs). 
The difference in global functioning (r=0.34, p=0.04) and severity of depression (r=0.29, 
p=0.31) between the two groups was of small effect.  
 
Although there was no association between rates of antidepressant use and subthreshold 
mania symptoms among all participants at baseline, whether such sub-threshold mania 
symptoms were in the context of antidepressant use could not be established. This was 
primarily because the information on subthreshold mania symptoms was mostly obtained 
from SCID-I/P notes and antidepressant use mostly obtained from clinical files.  
 
Discussion  
 
In a sample of help-seeking youth with a clinical high-risk state for psychosis, the numbers 
making a transition rate to mania over the 5 to 13-year follow-up period was low. 
Subthreshold manic symptoms, antidepressant use and lower functioning were associated 
with later episodes of mania.  
 
Comment [SJ6]: I think you need to 
describe the analyses in this table a 
bit, particularly the difference in 
mania symptom frequency 
Overall, the association with subthreshold manic symptoms points to the utility of the 
prodromal approach for mania particularly in staging models for severe mental disorders 
28
. 
Previous prospective studies 
29,30
 have also identified the occurrence of subthreshold manic 
symptoms prior to threshold manic episodes. The higher prevalence of antidepressant use 
may point to their potential contribution in switch from depression to mania 
31
. Alternatively, 
this may also indicate that persons with greater severity of depression may beare more likely 
to be prescribed antidepressant medication, consistent with clinical practice guidelines. 
Greater severity of depression has been previously identified to be associated with transition 
to mania among adolescents 
32
.   
 
The identified association with lower functioning may point to the possibility of this being 
associated with the incipient risk of transition to psychosis 
33
, which occurred in a majority of 
the UHR-manic sample. Thus, lower functioning could represent a clinical phenotype that 
has greater risk of transition to BD with psychosis, as outlined in staging models for this 
disorder 
34
. This has been supported by the finding of lower psychosocial functioning in 
people with comorbid psychosis in the months following an acute mood episode in BD 
35
.  
 
Limitations: The small number of conversions to mania in the cohort limited the power to 
detect smaller differences between groups.  However, the small number of conversions to 
mania is itself indicative of the possibility that samples with standard UHR criteria for 
psychoses may be relatively less useful in prevention paradigms for mania. This may be 
consistent with the low rate of incident BD reported in a large cohort of UHR participants 
from North America, though the length of follow-up in that study may have been lower 
36
. 
The confounding effect of the risk for psychosis in the sample is also an important 
consideration. A comparison group that later developed schizophrenia may have facilitated 
Comment [SJ7]: ‘like predicts like’, 
not surprising really! 
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examination of factors more specific for BD. However, given the high genetic and/or clinical 
loading for psychosis at baseline for all participants, as well as the large proportion that also 
transitioned to psychosis by follow-up, it was not possible to parse out the risk for psychosis 
in the current sample. Determination of diagnosis of eight control participants and two manic 
participants using non-interview based means (i.e., mental health registries) may be another 
limitation. However, it is unlikely that significant episodes of mania were missed, as these 
usually lead to contact with public mental health services. The lack of availability of some 
data particularly with respect to substance use both at baseline and in the intervening time 
points before the onset of mania limits the ability of the study to control for these 
confounding variables. However, substance-induced manic episodes were excluded using 
SCID interviews. Lack of blinding and or extraction of data by independent raters may have 
increased the risk of observation and expectancy bias.  
 
Significance for pre-onset identification and interventions: This study validates the sub-
threshold symptom approach in predicting the onset of mania. The identified characteristics 
may help improve risk prediction tools 
37,38
 for the onset of mania among help-seeking young 
people with an at-risk mental state for psychosis but possibly also other help-seeking young 
people with clinical symptoms, distress or family history. The Bipolar At-Risk (BAR) criteria 
are an example of such a risk prediction tool 
38
, which have been associated with prospective 
transition risks of 11% within one year of follow-up 
39
. These criteria incorporate concepts of 
subthreshold mania, cyclothymic features, depression and genetic risk among youth at a 
similar age group as those with UHR criteria. Incorporation of reduced functioning in such 
criteria may be important given the association with transition to mania and/or psychosis. 
This finding also points to the possible trans-diagnostic significance of deterioration in 
functioning prior to the onset of severe mental disorders. The trans-diagnostic enriching of 
Comment [SJ10]: This sentence is 
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these disorders is also indicated by the finding that those with UHR criteria and baseline BD 
were at a greater risk of transition to psychosis in short to medium term follow-up 
40
, a 
finding that was not identified with non-bipolar depressive mood disorders or anxiety 
disorders. The association with antidepressant use may be of clinical relevance in considering 
the risks of prescription of these medications for help-seeking young people when other risk 
factors of latent bipolarity such as subthreshold manic symptoms or family history of severe 
mental disorders are present. Future well-powered cohort studies with cross-diagnostic 
outcomes will help clarify the predictive power of these risk factors. 
 
Conclusions 
Subthreshold symptoms of mania, antidepressant use as well as lower global functioning in 
UHR patients at baseline should raise clinical concern about the possibility of transition to 
manic episodes with or without comorbid psychosis. Incorporation of these factors into at-
risk states for psychoses may help develop broader cross-diagnostic risk criteria among help-
seeking youth.  
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Table 1: Descriptive characteristics of participants who developed mania (UHR M, n= 18) and those who did not transition to psychosis or mania (UHR NT, 
n= 18) at follow-up   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic   Developed Mania  
(UHR M) (n=18) 
Did not develop mania or 
psychosis (UHR NT) (n=18) 
Age, in years M±SD 28.19±4.91 28.77±5.06 
Gender % (n)  55.56 (10) 55.56 (10) 
Length of follow-up, years M±SD 9.50±2.38 9.66±2.16 
Diagnostic ascertainment of mania    
Structured assessment % (n) 88.89 (16) 55.56 (10) 
State-wide registry diagnosis % (n) 12.11 (2)  44.44 (8)  
Primary diagnosis on follow-up  n Bipolar I disorder (n= 14) 
Schizoaffective disorder- 
manic type (n =4)  
Major depressive disorder (n= 8) 
Substance use disorder (n= 2) 
Anxiety disorder (n= 2) 
Brief psychotic disorder (n=1)  
Dissociative disorder (n= 1) 
No formal diagnosis (n =4)  
Transition to psychosis threshold % (N) 77.78 (14) 0.00 (0)  
Table 2: Baseline characteristics of youth who later developed manic episodes compared to a subgroup who did not develop mania or threshold 
psychosis (N= 36) 
Characteristic Measure N (pairs) Developed Mania  
(UHR-M)* 
Did not develop  
Mania or psychosis  
(UHR-NT)
# 
Statistic P-value 
Age at baseline M (SD) 18 19.89±3.89 19.39±3.48 Z=-0.28 0.777 
Symptom domains       
Subthreshold (hypo)manic symptoms % (n) 14 58.82 (10) 0 (0)  0.008 
Subthreshold bipolar disorder^ % (n) 13 35.29 (6) 0 (0)  0.063 
Major depression % (n) 14 76.47 (13) 54.54 (6)  0.375 
Cannabis use- Lifetime % (n) 13 64.70 (11) 64.28 (9)  1.000 
Antidepressant use- Lifetime % (n) 12 76.47 (13) 38.46 (5)  0.031 
Family history       
Family history of Bipolar Disorder % (n) 17 23.52 (4) 0 (0)  0.125 
Family history of Major Depression % (n) 14 6.67 (1) 25.00 (4)  0.375 
Family history of Schizophrenia spectrum disorder % (n) 17 50.00 (9) 35.29 (6)  0.754 
Family history of Bipolar or a Psychotic Disorder % (n) 17 55.56 (10) 35.29 (6)  0.549 
  
 
 
 
 
 
 
 
^ Subthreshold Bipolar disorder was defined to be equivalent to ‘Other specified Bipolar Disorder’ in DSM 5;   
 
 
 
 
 
Functioning       
Global Assessment of Functioning M (SD) 18 55.56±9.02 62.33±12.33 Z=-2.04 0.041 
Heinrich’s Quality of Life Scale M (SD) 18 84.17±33.38 82.06±22.79 Z=-0.61 0.542 
Symptom severity       
Scale for Assessment of Negative Symptoms % (n) 18 17.50±10.59 13.94±9.67 Z=-0.96 0.338 
Brief Psychiatric Rating Scale total % (n) 18 45.72±7.81 45.72±10.03 Z=-0.02 0.981 
Hamilton Anxiety Rating Scale  % (n) 11 17.64±9.27 14.18±8.72 Z=-0.98 0.327 
Hamilton Depression Rating Scale % (n) 12 25.00±15.69 18.25±12.81 Z=-1.02 0.307 
